Literature DB >> 31298412

MiR-296-5p inhibits cell invasion and migration of esophageal squamous cell carcinoma by downregulating STAT3 signaling.

Z-Z Wang1, Y-R Luo, J Du, Y Yu, X-Z Yang, Y-J Cui, X-F Jin.   

Abstract

OBJECTIVE: Many studies have emphasized the function of microRNA-296 (miR-296) that inhibits tumor formation. To some extent, the role of miR-296 in esophageal squamous cell carcinoma (ESCC) remains misleading. Therefore, the current research was designed to investigate the regulatory mechanisms of miR-296 and signal transducer and activator of transcription 3 (STAT3) in ESCC. PATIENTS AND METHODS: The mRNA expression of miR-296-5p and STAT3 in ESCC tissues or cell lines was measured via quantitative Real Time-Polymerase Chain Reaction (qRT-PCR). The protein level of STAT3 was measured by Western blotting assay. The Luciferase reporter assay was used to verify the binding sites between miR-296-5p and STAT3. The transwell assay was employed to identify cell migration and invasion.
RESULTS: Down-regulation of miR-296-5p was detected in ESCC tissues and cell lines (p<0.01). Additionally, miR-296-5p was found to target STAT3 directly. Functionally, up-regulation of miR-296-5p or down-regulation of STAT3 significantly inhibited cell migration and invasion in ESCC.
CONCLUSIONS: MiR-296-5p inhibited cell invasion and migration in ESCC by downregulating STAT3. The overexpression of miR-296-5p by targeting STAT3 suppressed tumorigenesis of ESCC cells.

Entities:  

Year:  2019        PMID: 31298412     DOI: 10.26355/eurrev_201906_18185

Source DB:  PubMed          Journal:  Eur Rev Med Pharmacol Sci        ISSN: 1128-3602            Impact factor:   3.507


  8 in total

1.  Exploring the underlying molecular mechanism of liver cancer cells under hypoxia based on RNA sequencing.

Authors:  Xin Zhao; Wenpeng Liu; Baowang Liu; Qiang Zeng; Ziqiang Cui; Yang Wang; Jinglin Cao; Qingjun Gao; Caiyan Zhao; Jian Dou
Journal:  BMC Genom Data       Date:  2022-05-19

2.  DICER1-AS1 Promotes the Malignant Behaviors of Colorectal Cancer Cells by Regulating miR-296-5p/STAT3 Axis.

Authors:  Chuanyu Ma; Ning Ma; Lili Qin; Chuanna Miao; Minglei Luo; Shuhong Liu
Journal:  Cancer Manag Res       Date:  2020-10-13       Impact factor: 3.989

3.  Novel Single Inhibitor of HDAC6/8 and Dual Inhibitor of PI3K/HDAC6 as Potential Alternative Treatments for Prostate Cancer.

Authors:  Fabiana Sélos Guerra; Daniel Alencar Rodrigues; Carlos Alberto Manssour Fraga; Patricia Dias Fernandes
Journal:  Pharmaceuticals (Basel)       Date:  2021-04-21

4.  LncRNA NEAT1 Promotes Proliferation, Migration And Invasion Via Regulating miR-296-5p/CNN2 Axis In Hepatocellular Carcinoma Cells.

Authors:  Yandong Li; Xiyan Ding; Shuqiu Xiu; Guobin Du; Yahui Liu
Journal:  Onco Targets Ther       Date:  2019-11-18       Impact factor: 4.147

5.  lncRNA FGD5-AS1 Regulates Bone Marrow Stem Cell Proliferation and Apoptosis by Affecting miR-296-5p/STAT3 Axis in Steroid-Induced Osteonecrosis of the Femoral Head.

Authors:  Yadi Wu; Lun Fang; Yong Gao; Zhiqiu Zhao; Lu Zhou; Gang Zhang
Journal:  J Healthc Eng       Date:  2022-02-12       Impact factor: 2.682

6.  Molecular mechanism, regulation, and therapeutic targeting of the STAT3 signaling pathway in esophageal cancer (Review).

Authors:  Rui-Jie Ma; Chao Ma; Kang Hu; Meng-Meng Zhao; Nan Zhang; Zhi-Gang Sun
Journal:  Int J Oncol       Date:  2022-07-20       Impact factor: 5.884

7.  Exosomal lncRNA FAM225A accelerates esophageal squamous cell carcinoma progression and angiogenesis via sponging miR-206 to upregulate NETO2 and FOXP1 expression.

Authors:  Chunyu Zhang; Yan Luo; Jingjing Cao; Xiaoyu Wang; Zhiwei Miao; Guoqing Shao
Journal:  Cancer Med       Date:  2020-10-02       Impact factor: 4.452

8.  Long non‑coding RNA PLK1S1 was associated with renal cell carcinoma progression by interacting with microRNA‑653 and altering C‑X‑C chemokine receptor 5 expression.

Authors:  Weiyuan Li; Dengke Yang; Yu Zhang; Shutian Zhao; Dong Li; Min Liu
Journal:  Oncol Rep       Date:  2020-08-19       Impact factor: 3.906

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.